EP1656128A4 - Acne vulgaris-behandlung und verwendungsverfahren - Google Patents
Acne vulgaris-behandlung und verwendungsverfahrenInfo
- Publication number
- EP1656128A4 EP1656128A4 EP03818329A EP03818329A EP1656128A4 EP 1656128 A4 EP1656128 A4 EP 1656128A4 EP 03818329 A EP03818329 A EP 03818329A EP 03818329 A EP03818329 A EP 03818329A EP 1656128 A4 EP1656128 A4 EP 1656128A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- acne vulgaris
- ethoxylate
- composition
- exchanged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 58
- 206010000496 acne Diseases 0.000 title claims abstract description 51
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 33
- -1 polyethylene Polymers 0.000 claims abstract description 12
- 239000004698 Polyethylene Substances 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 229920000573 polyethylene Polymers 0.000 claims abstract description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000011324 bead Substances 0.000 claims abstract description 7
- 108700004121 sarkosyl Proteins 0.000 claims abstract description 7
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims abstract description 7
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000004166 Lanolin Substances 0.000 claims abstract description 6
- 239000006260 foam Substances 0.000 claims abstract description 6
- 229940039717 lanolin Drugs 0.000 claims abstract description 6
- 235000019388 lanolin Nutrition 0.000 claims abstract description 6
- 238000005201 scrubbing Methods 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003381 stabilizer Substances 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 2
- 229940071089 sarcosinate Drugs 0.000 claims 3
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000012749 thinning agent Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 5
- 230000000699 topical effect Effects 0.000 abstract description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000007720 emulsion polymerization reaction Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- IEORSVTYLWZQJQ-UHFFFAOYSA-N 2-(2-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=CC=C1OCCO IEORSVTYLWZQJQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to a composition including surfactants for the treatment of acne vulgaris. Methods of use are also included ⁇ . BACKGROUND OF THE INVENTION AND PRIOR ART Acne vulgaris (or "acne") is a disorder of the sebaceous glands. It is characterized by lesions that are either non-inflammatory or inflammatory papules and nodules. Non-inflammatory papules may be open, commonly referred to as “blackheads", or closed, commonly referred to as “whiteheads”. As a group, non- inflammatory papules are called comedones.
- a topical treatment for acne 5 vulgaris a topical treatment for acne 5 vulgaris.
- a method is provided for applying a composition of 6 substances to the infected area, working the composition into the infected area, and 7 removing the composition from the infected area.
- the composition comprises at least 8 one ethoxylate in combination with Sodium Lauroyl Sarcosinate (or "SLS").
- SLS Sodium Lauroyl Sarcosinate
- An inert 9 scrubbing agent such as polyethylene beads, can also be included to the formula.
- Acetylated lanolin alcohol, a second ethoxylate, EDTA, a foam stabilizer, and water can 11 also be added to the composition without effecting performance.
- Other formulas that keep the polarity similar to that of the inventive formula will 13 also work. To keep the polarity similar, it is necessary for the compound to have similar 14 characteristics, such as Carbon chains, carbonyl groups, Nitrogen bound to Carbon, 15 Aromatic ring(s), Oxylate groups, and appropriate functional groups at the ends of the 16 individual molecules.
- the ideal substitute chemicals would have all of the characteristics 17 mentioned above, but it is not necessary to have every one of those as listed.
- the cutting agent must be added only in 2 sufficient amount that it promotes flow but does not effect the action of the composition. 3
- an sufficient amount of the composition is used to cover the infected area, 4 the composition is applied to an infected area and worked over the area by a scrubbing 5 motion. After sufficient time has elapsed to ensure that the infected area has been 6 adequately exposed to the composition such that they area feels clean, approximately ten 7 to thirty seconds for the typical person, the area is rinsed cleaned.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2003/025207 WO2005018629A1 (en) | 2003-08-12 | 2003-08-12 | Treatment for acne vulgaris and method of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1656128A1 EP1656128A1 (de) | 2006-05-17 |
| EP1656128A4 true EP1656128A4 (de) | 2007-02-28 |
Family
ID=34215304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03818329A Withdrawn EP1656128A4 (de) | 2003-08-12 | 2003-08-12 | Acne vulgaris-behandlung und verwendungsverfahren |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1656128A4 (de) |
| JP (1) | JP2007521234A (de) |
| AU (1) | AU2003264053A1 (de) |
| CA (1) | CA2535550A1 (de) |
| WO (1) | WO2005018629A1 (de) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9156914B2 (en) | 2006-12-19 | 2015-10-13 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
| EP2557090A3 (de) | 2006-12-19 | 2013-05-29 | Ablynx N.V. | Gegen GPCRs gerichtete Aminosäuresequenzen und Polypeptide damit zur Behandlung von Krankheiten und Störungen im Zusammenhang mit GPCR |
| FR2923383B1 (fr) * | 2007-11-08 | 2010-03-19 | Oreal | Utilisation d'un sarcosinate n-acyle comme agent anti-adhesion microbienne. |
| US8975382B2 (en) | 2007-11-27 | 2015-03-10 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
| JP2011525476A (ja) | 2008-03-05 | 2011-09-22 | アブリンクス エン．ヴェー． | 新規の抗原結合二量体複合体、その製造方法及び使用 |
| EP2947097A1 (de) | 2008-04-07 | 2015-11-25 | Ablynx N.V. | Gegen Notch-Signalwege gerichtete Aminosäuresequenzen und Verwendungen davon |
| CN102099378B (zh) | 2008-05-16 | 2016-01-20 | 埃博灵克斯股份有限公司 | 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽 |
| WO2009147248A2 (en) | 2008-06-05 | 2009-12-10 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
| US9005963B2 (en) | 2008-10-14 | 2015-04-14 | Ablynx N.V. | Amino acid sequences directed against cellular receptors for viruses and bacteria |
| EP2364328A2 (de) | 2008-12-10 | 2011-09-14 | Ablynx NV | Gegen das angiopoietin/tie-system gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit angiogenese in zusammenhang stehenden krankheiten und störungen |
| EP2403873A1 (de) | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Neue antigenbindende dimerkomplexe, verfahren zur herstellung/vermeidung und anwendungen davon |
| BRPI1013877A2 (pt) | 2009-04-10 | 2017-08-15 | Ablynx Nv | Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r |
| EP2424889B1 (de) | 2009-04-30 | 2015-08-12 | Ablynx N.V. | Verfahren zur herstellung von domänenantikörpern |
| SMT201700376T1 (it) | 2009-06-05 | 2017-09-07 | Ablynx Nv | Costrutti trivalenti di nanobody anti-virus respiratorio sinciziale umano (hrsv) per la prevenzione e/o il trattamento di infezioni del tratto respiratorio |
| US9150640B2 (en) | 2009-07-10 | 2015-10-06 | Ablynx N.V. | Method for the production of variable domains |
| PT2473527T (pt) | 2009-09-03 | 2017-02-27 | Ablynx Nv | Formulações estáveis de polipéptidos e seus usos |
| US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| EP3309176A1 (de) | 2009-12-14 | 2018-04-18 | Ablynx N.V. | Immunoglobulin variable einzeldomänen-antikörper gegen ox40l, konstrukte und therapeutische verwendung |
| WO2011083141A2 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| CA2787718C (en) | 2010-02-11 | 2018-05-15 | Ablynx Nv | Methods and compositions for the preparation of aerosols |
| WO2011117423A1 (en) | 2010-03-26 | 2011-09-29 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
| PH12012502272A1 (en) | 2010-05-20 | 2017-07-26 | Ablynx Nv | Biological materials related to her3 |
| WO2011161263A1 (en) | 2010-06-25 | 2011-12-29 | Ablynx Nv | Pharmaceutical compositions for cutaneous administration |
| EP2632946B1 (de) | 2010-10-29 | 2017-12-06 | Ablynx N.V. | Verfahren zur herstellung von variablen immunglobulin-einzeldomänen |
| RS59589B1 (sr) | 2010-11-05 | 2019-12-31 | Zymeworks Inc | Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu |
| CU24111B1 (es) | 2010-11-08 | 2015-08-27 | Novartis Ag | Polipéptidos que se enlazan a cxcr2 |
| CA2831415A1 (en) | 2011-03-28 | 2012-10-04 | Ablynx Nv | Bispecific anti-cxcr7 immunoglobulin single variable domains |
| WO2012130872A1 (en) | 2011-03-28 | 2012-10-04 | Ablynx Nv | Method for producing solid formulations comprising immunoglobulin single variable domains |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| EP3590950A1 (de) | 2011-05-09 | 2020-01-08 | Ablynx NV | Verfahren zur herstellung von einzelvariablen immunglobulindomänen |
| WO2012163887A1 (en) | 2011-05-27 | 2012-12-06 | Ablynx Nv | Inhibition of bone resorption with rankl binding peptides |
| IN2014CN00437A (de) | 2011-06-23 | 2015-04-03 | Ablynx Nv | |
| AU2012311443B2 (en) | 2011-09-23 | 2016-12-01 | Ablynx Nv | Prolonged inhibition of interleukin-6 mediated signaling |
| PL2773671T3 (pl) | 2011-11-04 | 2022-01-24 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc |
| JP6351572B2 (ja) | 2012-05-10 | 2018-07-04 | ザイムワークス，インコーポレイテッド | Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物 |
| US9499634B2 (en) | 2012-06-25 | 2016-11-22 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| JP6603209B2 (ja) | 2013-05-10 | 2019-11-06 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾 |
| EP2883883A1 (de) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| HUE044199T2 (hu) | 2014-10-10 | 2019-10-28 | Ablynx Nv | Inhalációs készülék légúti betegségek aeroszolos terápiájában való alkalmazásra |
| JP2017538779A (ja) | 2014-10-10 | 2017-12-28 | アブリンクス・エヌ・フェー | Ｒｓｖ感染の治療方法 |
| ES2772348T3 (es) | 2014-12-19 | 2020-07-07 | Ablynx Nv | Dímeros de Nanobody con uniones cisteína |
| EP3380517B1 (de) | 2015-11-27 | 2021-08-04 | Ablynx NV | Polypeptide zur hemmung von cd40l |
| SE543153C2 (en) | 2016-05-19 | 2020-10-13 | Biocool Ab | Aqueous hydrogen peroxide solution obtained from a dry composition comprising sodium percarbonate for skin treatment |
| CA3026108A1 (en) | 2016-06-10 | 2017-12-14 | Clarity Cosmetics Inc. | Non-comedogenic hair and scalp care formulations and method for use |
| WO2018007442A1 (en) | 2016-07-06 | 2018-01-11 | Ablynx N.V. | Treatment of il-6r related diseases |
| WO2018029182A1 (en) | 2016-08-08 | 2018-02-15 | Ablynx N.V. | Il-6r single variable domain antibodies for treatment of il-6r related diseases |
| US11098113B2 (en) | 2016-09-15 | 2021-08-24 | Vib Vzw | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
| CN117700549A (zh) | 2016-11-16 | 2024-03-15 | 埃博灵克斯股份有限公司 | 能够结合CD123和TCRα/β的T细胞募集多肽 |
| WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
| JP7186401B2 (ja) | 2017-02-28 | 2022-12-09 | フエー・イー・ベー・フエー・ゼツト・ウエー | タンパク質の経口送達のための手段及び方法 |
| US11891451B2 (en) | 2017-05-11 | 2024-02-06 | Vib Vzw | Glycosylation of variable immunoglobulin domains |
| CN118085076A (zh) | 2017-06-02 | 2024-05-28 | 埃博灵克斯股份有限公司 | 结合聚集蛋白聚糖的免疫球蛋白 |
| BR112019025147A2 (pt) | 2017-06-02 | 2020-06-23 | Merck Patent Gmbh | Polipeptídeos que ligam adamts5, mmp13 e aggrecan |
| US12129308B2 (en) | 2017-06-02 | 2024-10-29 | Merck Patent Gmbh | MMP13 binding immunoglobulins |
| PT3630847T (pt) | 2017-06-02 | 2024-11-21 | Merck Patent Gmbh | Imunoglobulinas que se ligam a adamts |
| WO2019016237A1 (en) | 2017-07-19 | 2019-01-24 | Vib Vzw | AGENTS FOR CONNECTING TO SERUM ALBUMIN |
| US11873347B2 (en) | 2017-10-31 | 2024-01-16 | Vib Vzw | Antigen-binding chimeric proteins and methods and uses thereof |
| US11999797B2 (en) | 2018-02-06 | 2024-06-04 | Ablynx N.V. | Methods of treating initial episode of TTP with immunoglobulin single variable domains |
| US11858960B2 (en) | 2018-03-01 | 2024-01-02 | Vrije Universiteit Brussel | Human PD-L1-binding immunoglobulins |
| CA3088676A1 (en) | 2018-03-23 | 2019-09-26 | Universite Libre De Bruxelles | Wnt signaling agonist molecules |
| JP7603600B2 (ja) | 2019-03-08 | 2024-12-20 | リンクシス ベスローテン フェンノートシャップ | 細胞増殖又は細胞分化に関与する受容体を標的にする内在化結合分子 |
| EP3976650A1 (de) | 2019-05-28 | 2022-04-06 | Vib Vzw | Krebsbehandlung durch abzielen auf plexine im immunbereich |
| WO2020239934A1 (en) | 2019-05-28 | 2020-12-03 | Vib Vzw | Cd8+ t-cells lacking plexins and their application in cancer treatment |
| GB201918279D0 (en) | 2019-12-12 | 2020-01-29 | Vib Vzw | Glycosylated single chain immunoglobulin domains |
| JP2023523600A (ja) | 2020-04-22 | 2023-06-06 | マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド | ヒトプログラム細胞死リガンド１（ｐｄ－ｌ１）を標的とする単一可変ドメイン抗体およびその誘導体 |
| WO2021229104A1 (en) | 2020-05-15 | 2021-11-18 | Université de Liège | Anti-cd38 single-domain antibodies in disease monitoring and treatment |
| WO2022060223A1 (en) | 2020-09-16 | 2022-03-24 | Linxis B.V. | Internalizing binding molecules |
| WO2022063957A1 (en) | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
| EP4216943A1 (de) | 2020-09-24 | 2023-08-02 | Vib Vzw | Kombination von p2y6-inhibitoren und immuncheckpoint-inhibitoren |
| PH12023500013A1 (en) | 2020-12-04 | 2024-03-11 | Tidal Therapeutics Inc | Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof |
| WO2022175392A1 (en) | 2021-02-17 | 2022-08-25 | Vib Vzw | Inhibition of slc4a4 in the treatment of cancer |
| CA3209052A1 (en) | 2021-02-19 | 2022-08-25 | Rafael Cristian CASELLAS | Single domain antibodies that neutralize sars-cov-2 |
| WO2022242892A1 (en) | 2021-05-17 | 2022-11-24 | Université de Liège | Anti-cd38 single-domain antibodies in disease monitoring and treatment |
| US20240360189A1 (en) | 2021-07-09 | 2024-10-31 | Luxembourg Institute Of Health (Lih) | Dimeric protein complexes and uses thereof |
| IL317461A (en) | 2022-06-08 | 2025-02-01 | Tidal Therapeutics Inc | Ionized Cationic Lipids and Lipid Nanoparticles and Methods of Synthesis and Use thereof |
| WO2024008755A1 (en) | 2022-07-04 | 2024-01-11 | Vib Vzw | Blood-cerebrospinal fluid barrier crossing antibodies |
| WO2024008274A1 (en) | 2022-07-04 | 2024-01-11 | Universiteit Antwerpen | T regulatory cell modification |
| WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| WO2024137731A2 (en) | 2022-12-21 | 2024-06-27 | Genzyme Corporation | Anti‑pd‑1×4‑1bb binding proteins |
| WO2024156881A1 (en) | 2023-01-27 | 2024-08-02 | Vib Vzw | CD8b-BINDING POLYPEPTIDES |
| WO2024156888A1 (en) | 2023-01-27 | 2024-08-02 | Vib Vzw | Cd163-binding conjugates |
| WO2024208816A1 (en) | 2023-04-03 | 2024-10-10 | Vib Vzw | Blood-brain barrier crossing antibodies |
| WO2024231348A1 (en) | 2023-05-11 | 2024-11-14 | Vib Vzw | Slc4a4/nbce1 inhibitors |
| WO2024251783A1 (en) | 2023-06-05 | 2024-12-12 | Sanofi | Predicting thermal stabilities of immunoglobulin single variable domains using machine-learning models |
| EP4483951A1 (de) | 2023-06-30 | 2025-01-01 | Université de Liège | Einzeldomänenantikörper zur hemmung der aktivität neutrophiler elastase |
| US12138428B1 (en) | 2024-01-24 | 2024-11-12 | Sanofi | Electronic add-on module and assembly of an electronic add-on module and a drug delivery device |
| US12144969B1 (en) | 2024-02-28 | 2024-11-19 | Sanofi | Attachment mechanism, module and assembly herewith |
| US12186538B1 (en) | 2024-05-10 | 2025-01-07 | Sanofi | Electronic add-on module and assembly of an electronic add-on module and a drug delivery device |
| US12213944B1 (en) | 2024-05-16 | 2025-02-04 | Genzyme Corporation | Fluid transfer device |
| US12171719B1 (en) | 2024-05-16 | 2024-12-24 | Genzyme Corporation | Fluid transfer device |
| US12226371B1 (en) | 2024-05-16 | 2025-02-18 | Genzyme Corporation | Fluid transfer device |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4147782A (en) * | 1976-06-24 | 1979-04-03 | William H. Rorer, Inc. | Pharmaceutical detergent composition |
| WO2000003686A2 (en) * | 1998-07-20 | 2000-01-27 | Sarlo Peter V | Acne treatment compositions |
| US6423746B1 (en) * | 1999-07-03 | 2002-07-23 | The William M. Yarbrough Foundation | Urushiol induced contact dermatitis and method of use |
| US20020183284A1 (en) * | 1999-07-03 | 2002-12-05 | Yarbrough William M. | Urushiol induced contact dermatitis solution |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1539031A (en) * | 1975-02-22 | 1979-01-24 | Beecham Group Ltd | Pharmaceutical compositions |
-
2003
- 2003-08-12 EP EP03818329A patent/EP1656128A4/de not_active Withdrawn
- 2003-08-12 CA CA002535550A patent/CA2535550A1/en not_active Abandoned
- 2003-08-12 AU AU2003264053A patent/AU2003264053A1/en not_active Abandoned
- 2003-08-12 WO PCT/US2003/025207 patent/WO2005018629A1/en active Application Filing
- 2003-08-12 JP JP2005508238A patent/JP2007521234A/ja not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4147782A (en) * | 1976-06-24 | 1979-04-03 | William H. Rorer, Inc. | Pharmaceutical detergent composition |
| WO2000003686A2 (en) * | 1998-07-20 | 2000-01-27 | Sarlo Peter V | Acne treatment compositions |
| US6423746B1 (en) * | 1999-07-03 | 2002-07-23 | The William M. Yarbrough Foundation | Urushiol induced contact dermatitis and method of use |
| US20020183284A1 (en) * | 1999-07-03 | 2002-12-05 | Yarbrough William M. | Urushiol induced contact dermatitis solution |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2005018629A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1656128A1 (de) | 2006-05-17 |
| AU2003264053A1 (en) | 2005-03-10 |
| WO2005018629A1 (en) | 2005-03-03 |
| CA2535550A1 (en) | 2005-03-03 |
| JP2007521234A (ja) | 2007-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005018629A1 (en) | Treatment for acne vulgaris and method of use | |
| US6423746B1 (en) | Urushiol induced contact dermatitis and method of use | |
| CA2256960C (en) | High glycerin containing anti-microbial cleansers | |
| US4395398A (en) | Dental hemostatic composition | |
| US9730870B2 (en) | Sodium hypochlorite-based body wash compositions | |
| AU2005300313B2 (en) | Topical pharmaceutical compositions containing an antiacne compound and antibiotic compound | |
| CN108066164B (zh) | 一种透明的复合型清洁组合物及其制备方法 | |
| JP2008533037A (ja) | 過酸化ベンゾイル組成物およびその使用方法 | |
| CA2614846C (en) | Acne treatment | |
| US10561626B2 (en) | Method for treating urushiol induced contact dermatitis | |
| MXPA06001668A (en) | Treatment for acne vulgaris and method of use | |
| JP2001504153A (ja) | 殺菌性ソープバー | |
| WO2002002104A1 (en) | Urushiol induced contact dermatitis treatment and method of use | |
| JP2668853B2 (ja) | 台所用洗剤 | |
| WO2000069403A1 (en) | Alpha amino acid composition and method for the treatment of skin | |
| CN111743793A (zh) | 一种洗手液及其制备方法 | |
| JPH0559889B2 (de) | ||
| JPH0324443B2 (de) | ||
| JP3293692B2 (ja) | ヨード配合砂場用殺菌剤組成物 | |
| JP2004131503A (ja) | 溶解性が高められたベータヒドロキシ酸とそれを用いて処方した高い効能の皮膚剥離剤 | |
| WO2004052358A1 (en) | Urushiol induced contact dermatitis treatment and method of use | |
| JP2007502289A (ja) | 刺咬性及び侵入性生物並びに寄生生物と蕁麻疹の治療用組成物、並びに使用方法 | |
| EP1982694B1 (de) | Antiödemzusammensetzung | |
| US20050037039A1 (en) | Composition for treatment of tinea pedis and method of use | |
| PL194901B1 (pl) | Sposób wytwarzania preparatu żelowego przeciwko trądzikowi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20060310 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20070126 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/085 20060101AFI20070122BHEP Ipc: A61P 17/10 20060101ALI20070122BHEP Ipc: A61K 31/198 20060101ALI20070122BHEP Ipc: A61K 45/06 20060101ALI20070122BHEP |
|
| 17Q | First examination report despatched |
Effective date: 20070404 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THE WILLIAM M. YARBROUGH FOUNDATION |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: WILLIAM M. YARBROUGH |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20070817 |